ID110460001 

ID110460001 is a full agonist of μ-opioid receptor and an agonist of δ-opioid receptor. ID110460001 exhibits high intrinsic efficacy for G protein pathway activation of μ-opioid receptor, and this property is not affected by the reduction in receptor quantity. ID110460001 acts only as a very weak partial agonist in the β-arrestin-2 pathway of both receptors, and binds to μ-opioid receptor via a specific mode. The efficacy of ID110460001 in the G protein pathway of δ-opioid receptor is sensitive to changes in receptor quantity. ID110460001 can be used in pain-related research^[1].

ID110460001 (eight-point concentration gradients; 20 min pre-incubation with irreversible antagonists) acts as a full agonist for the G protein pathway and a very weak partial agonist for the β-arrestin-2 pathway at both OPRM-overexpressing and OPRD-overexpressing HEK-293 cells, with high intrinsic efficacy at OPRM as demonstrated by maintained Emax under reduced receptor population conditions^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

340.42

C₂₀H₂₄N₂O₃

1110883-26-5

O=C(NCC(C=1C=CC=CC1)N(C)C)CC2=CC=C3OCCOC3=C2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Lee JH, et al. Discovery of μ,δ-Opioid Receptor Dual-Biased Agonists That Overcome the Limitation of Prior Biased Agonists. ACS Pharmacol Transl Sci. 2021;4(3):1149-1160. Published 2021 Apr 6.  [Content Brief]